Combining the Glasgow Prognostic Score and Serum Carbohydrate Antigen 19-9 Level Improves the Ability to Predict Early Recurrence in Resected Pancreatic Cancer Patients Receiving Adjuvant Gemcitabine

(a) Disease-free survival curves based on the Glasgow Prognostic Score (GPS). The 1-year disease-free survival rates of the patients with a GPS of 0 (solid line) or 1 or 2 (dotted line) were 36.8% and 14.4%, respectively. (b) Overall survival curves based on the Glasgow Prognostic Score (GPS). The 1-year overall survival rates of the patients with a GPS of 0 (solid line) or 1 or 2 (dotted line) were 89.2% and 58.0%, respectively. (c) Disease-free survival curves based on the CA19-9 level. The 1-year disease-free survival rates of the patients with a CA19-9 level below 180 U/ml (solid line) or 180 U/ml or above (dotted line) were 36.4% and 5.9% (not reached), respectively. (d) Overall survival curves based on the CA19-9 level. The 1-year overall survival rates of the patients with a CA19-9 level below 180 U/ml (solid line) or 180 U/ml or above (dotted line) were 89.1% and 40.3%, respectively.